Literature DB >> 15241822

Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women.

Lukas A Hefler1, Clemens B Tempfer, Christoph Grimm, Antje Lebrecht, Eva Ulbrich, Georg Heinze, Sepp Leodolter, Christian Schneeberger, Manfred W Mueller, Axel Muendlein, Heinz Koelbl.   

Abstract

BACKGROUND: Genes encoding enzymes involved in estrogen metabolism are held to be candidate genes for associations with breast disease. In these candidate genes, no critical combination of single-nucleotide polymorphisms (SNPs) for assessing breast carcinoma risk has been reported to date.
METHODS: In a large case-control study, the authors investigated 10 estrogen-metabolizing SNPs in 396 patients with breast carcinoma, 154 patients with fibroadenoma, and 1936 healthy control patients without breast carcinoma in their personal history. The following 10 SNPs were analyzed using sequencing-on-chip technology via a solid-phase polymerase chain reaction assay performed on oligonucleotide microarrays: catechol-O-methyltransferase Val158Met G-->A, 17-beta-hydroxysteroid dehydrogenase type 1 vIV A-->C, cytochrome P-450 (CYP) family 17 A2 allele T-->C, CYP1A1-1 MspI restriction fragment length polymorphism (RFLP) T-->C, CYP1A1-2 Ile462Val A-->G, CYP19-1 Trp39Arg T-->C, CYP19-2 Arg264Cys C-->T, CYP19-3 Cys1558Thr C-->T, steroid-5-alpha reductase type 2 Val89Leu G-->C, and vitamin D receptor BsmI RFLP. A total of 21,350 genotypes were evaluated. Associations and two-way interaction models were calculated using stepwise logistic regression.
RESULTS: In a multiple model, CYP1A1-1 (P = 0.004) and CYP1A1-2 (P = 0.03) were found to be associated with significantly decreased and increased risks of breast carcinoma, respectively. When two-way interactions involving investigated SNPs were ascertained, no significant interactions among polymorphisms were noted. Comparison of patients with fibroadenoma with control patients revealed significantly increased and decreased risks of fibroadenoma when the mutant alleles of CYP17 (P = 0.02) and CYP1A1-1 (P = 0.04), respectively, were present.
CONCLUSIONS: The authors obtained the first SNP data indicating that CYP17 and CYP1A1-1 play a role in the pathogenesis of fibroadenoma. Although the authors were not able to develop interaction models involving SNPs, they did provide evidence that CYP1A1 is a low-penetrance susceptibility gene with respect to breast carcinoma in a large series of Caucasian women. Copyright 2004 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15241822     DOI: 10.1002/cncr.20361

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

1.  Fruit and vegetable intakes are associated with lower risk of breast fibroadenomas in Chinese women.

Authors:  Zakia Coriaty Nelson; Roberta M Ray; Chunyuan Wu; Helge Stalsberg; Peggy Porter; Johanna W Lampe; Jackilen Shannon; Neilann Horner; Wenjin Li; Wenwan Wang; Yongwei Hu; Daoli Gao; David B Thomas
Journal:  J Nutr       Date:  2010-05-19       Impact factor: 4.798

2.  Associations between vitamin D receptor polymorphisms and breast cancer risk.

Authors:  Jie Wang; Qi He; Yu-Guo Shao; Min Ji; Wei Bao
Journal:  Tumour Biol       Date:  2013-07-31

3.  A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives.

Authors:  Zhen Hu; Chuan-Gui Song; Jing-Song Lu; Jian-Min Luo; Zhen-Zhou Shen; Wei Huang; Zhi-Ming Shao
Journal:  J Cancer Res Clin Oncol       Date:  2007-06-12       Impact factor: 4.553

4.  Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China.

Authors:  Chu Chen; Lori C Sakoda; Jennifer A Doherty; Melissa M Loomis; Sherianne Fish; Roberta M Ray; Ming Gang Lin; Wenhong Fan; Lue Ping Zhao; Dao Li Gao; Helge Stalsberg; Ziding Feng; David B Thomas
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-12       Impact factor: 4.254

5.  Meta-analysis of genetic polymorphisms in xenobiotic metabolizing enzymes and their association with breast cancer risk.

Authors:  Tajamul Hussain; Salman Alrokayan; Upadhyay Upasna; Manickam Pavithrakumari; Jaganathan Jayapriya; Vijay Kumar Kutala; Shaik Mohammad Naushad
Journal:  J Genet       Date:  2018-06       Impact factor: 1.166

6.  Impact of xenobiotic-metabolizing gene polymorphisms on breast cancer risk in South Indian women.

Authors:  Taruna Rajagopal; Arun Seshachalam; Krishna Kumar Rathnam; Arunachalam Jothi; Srikanth Talluri; Sivaramakrishnan Venkatabalasubramanian; Nageswara Rao Dunna
Journal:  Breast Cancer Res Treat       Date:  2021-01-04       Impact factor: 4.872

7.  A non-synonymous coding change in the CYP19A1 gene Arg264Cys (rs700519) does not affect circulating estradiol, bone structure or fracture.

Authors:  Jenny Z Wang; Mandeep S Deogan; Joshua R Lewis; Shelby Chew; Ben H Mullin; Tegan J McNab; Scott G Wilson; Evan Ingley; Richard L Prince
Journal:  BMC Med Genet       Date:  2011-12-20       Impact factor: 2.103

8.  Vitamin D receptor polymorphisms (FokI, BsmI) and breast cancer risk: association replication in two case-control studies within French Canadian population.

Authors:  Marc Sinotte; François Rousseau; Pierre Ayotte; Eric Dewailly; Caroline Diorio; Yves Giguère; Sylvie Bérubé; Jacques Brisson
Journal:  Endocr Relat Cancer       Date:  2008-08-21       Impact factor: 5.678

9.  Vitamin D receptor gene polymorphisms and prognosis of breast cancer among African-American and Hispanic women.

Authors:  Dhruva K Mishra; Yanyuan Wu; Marianna Sarkissyan; Suren Sarkissyan; Zujian Chen; Xiying Shang; May Ong; David Heber; H Phillip Koeffler; Jaydutt V Vadgama
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

Review 10.  Association of COMT Val158Met polymorphism and breast cancer risk: an updated meta-analysis.

Authors:  Xue Qin; Qiliu Peng; Aiping Qin; Zhiping Chen; Liwen Lin; Yan Deng; Li Xie; Juanjuan Xu; Haiwei Li; Taijie Li; Shan Li; Jinmin Zhao
Journal:  Diagn Pathol       Date:  2012-10-08       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.